Davita Inc. (DVA) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $3.82 vs ~$3.78 consensus
DaVita earnings narrowly beat expectations, and 2026 guidance improved at the low end—but weak treatment growth and higher care costs remain.
DaVita remains a dialysis-led healthcare operator using its core U.S. business to expand integrated kidney care and value-based arrangements; the latest quarter shows that expansion continuing, but the core operating engine is not accelerating materially. Its prior-quarter outlook already pointed to a roughly $2.2 billion adjusted operating-income year, so the new information is the earnings beat and the higher floor—not a wholesale change in direction.
The quarter modestly cleared expectations. Adjusted diluted EPS was $3.82 versus a published consensus near $3.78, while revenue was $3.578 billion versus expectations around $3.53 billion; that makes this a beat, but not a dramatic one. GAAP diluted EPS was $3.40, reduced by a China-related impairment that had no cash impact. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guidance |
|---|---|---|---|
| Revenue ($ millions) (Income Statement) | $3,578 (+4.6%) | $3,420 | ~$3,530 |
| Adjusted diluted EPS (Net income reconciliation) | $3.82 | — | ~$3.78 |
| Adjusted operating income ($ millions) (Operating income) | $561 (-3.1%) | — | — |
| Operating margin (Business metrics) | 14.0% | — | — |
| Free cash flow ($ millions) (Cash flow) | $276 (-54.3%) | $604 | — |
| 2026 adjusted EPS guidance (Guidance) | $14.30–$15.20 | — | Prior low: $14.10 |
The quality of the beat is mixed beneath the headline. Adjusted operating income fell to $561 million from $579 million in the second quarter, and adjusted margin declined to 15.7% from 16.3%. Treatment volume grew only 0.4% on a normalized, non-acquired basis, while patient-care cost per treatment rose $2.82 sequentially to $280.22. 〔1〕 〔2〕
Management improved the downside protection, not the full-year ceiling. The low end of adjusted operating-income guidance rose from $2.150 billion to $2.175 billion and the low end of adjusted EPS guidance from $14.10 to $14.30, while the high ends and free-cash-flow range stayed unchanged. That is a useful confidence signal, but it is a partial raise rather than a broad outlook upgrade.
Integrated kidney care is expanding faster than the dialysis base. Risk-based IKC patients increased to 80,800 from 64,900 in the prior quarter, with annualized medical spend rising to $6.4 billion from $5.8 billion. The growth supports DaVita’s longer-term shift toward value-based care, although these arrangements carry estimation uncertainty and have not yet displaced the dialysis business as the main earnings driver.
Bottom line: This was a narrow earnings beat with a modest improvement to the 2026 downside case, not a clean acceleration story. DaVita’s core volume remains subdued and costs are rising, but the expanding IKC platform and raised guidance floor keep the business read slightly better than expected.
Q4 2026 earnings report
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!